In an era of rapid medical advancement, one of the most groundbreaking innovations bringing new hope to humanity is the Long-Acting PrEP Injection — a preventive treatment that reduces the risk of HIV infection by more than 99%, without the need to take daily pills. In the past, people relied on daily PrEP tablets (Pre-Exposure
Tag Archives: Lenacapavir
19
Jun
Jun
On June 18, 2025, the U.S. Food and Drug Administration (FDA) officially approved Yeztugo®—the brand name for lenacapavir, developed by Gilead Sciences—as the world’s first and only biannual injectable PrEP (Pre-Exposure Prophylaxis) for HIV prevention. This marks a major milestone in medical advancement that has drawn global attention. The approval is based on international clinical